logo
This common development mistake could cost you millions — here's how to fix it

This common development mistake could cost you millions — here's how to fix it

Would you buy a luxury car one part at a time? Order the engine from one supplier, the brakes from another, and the frame from a third, hoping it all comes together in the end? Probably not.
Yet that's exactly how many commercial real estate projects are still being delivered—piecemeal.
Developers often hire separate firms for architecture, engineering, and construction, then act as the go-between to keep everything aligned. That approach adds risk at every stage. It creates more opportunities for delays, disconnects, change orders, rework, and cost overruns that blow up your pro forma. And yes, it's costing millions.
The #1 mistake we see from Developers across South Florida?
Relying on siloed teams to deliver a project that should be designed and built as one cohesive system from day one.
A Smarter, Integrated Model
expand
.
FINFROCK is a fully integrated design-builder with decades of experience delivering commercial real estate projects across Florida. That means we're your architect, structural engineer, precast manufacturer, and general contractor—under a single contract.
When developers choose FINFROCK, they don't have to referee between competing interests or wait for one team to fix what another overlooked. Everything is coordinated from the start.
Our process provides:
Early pricing clarity, even before construction documents are complete
Fewer surprises, because design and buildability are aligned from day one
Faster construction, thanks to our offsite precast manufacturing and modular approach
Simplified communication, with a single point of responsibility
Modular Construction That's Anything But Generic
FINFROCK's proprietary precast system, built around our DualDeck® technology, allows us to cast floor and ceiling units together—complete with integrated MEPFP systems. These components are manufactured off-site and assembled on-site like a well-choreographed machine.
The result?
Clean interior finishes
Consistent quality
Reduced coordination between trades
Speed that competitors can't match
Long structural spans for premium designs
This isn't one-size-fits-all. Our system is flexible enough to accommodate complex layouts, luxury finishes, ground-floor retail, and structured parking —all designed with your budget in mind.
expand
Developers Already Making the Switch
Across Florida, forward-thinking developers are choosing FINFROCK to deliver projects in:
Multifamily
Hospitality
Office and mixed-use
Student housing
Structured parking
They're not just avoiding headaches— they're hitting the market months earlier and saving millions in the process.
Stop Piecing It All Together
The biggest hidden cost in development? Trying to be your own project referee.
With FINFROCK, your entire project is designed, priced, manufactured, and built by one partner who thinks like a developer—and delivers like one too. With decades of experience working closely with AHJs across Florida, FINFROCK knows how to navigate approvals and keep projects moving. Our patented DualDeck® Building System is fire-rated and manufactured in a state-certified facility—giving developers confidence in both performance and compliance.
If you're still hiring a separate architect, GC, and structural team—maybe it's time to stop making that same expensive mistake.
Want to avoid delays, redesigns, and budget bloat?
Call FINFROCK before your architect. We'll design it right—with construction in mind.
FINFROCK, Florida's top design-builder, integrates architects, engineers, manufacturing, and construction professionals to lower costs, speed-up schedules, and minimize building risk for owners. With over 75+ years' experience, FINFROCK has delivered award-winning buildings including parking, hotels, and luxury multi-family developments, earning top industry rankings and multiple design excellence awards.
Scott Zdroik is the Business Development Director for FINFROCK in South Florida. With a sharp focus on expanding partnerships in the multifamily, healthcare, and commercial sectors, Scott leads client outreach, drives strategic growth initiatives, and cultivates long-term relationships across the region.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash

The Hill

time6 hours ago

  • The Hill

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month's supply of Novo Nordisk's semaglutide pen products for $499 through GoodRx. The list price for a monthly supply of a product like Ozempic is normally around $1,000 or more without insurance. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' GoodRx CEO and President Wendy Barnes said in a statement. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them,' added Barnes. 'It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' This is the most recent in similar moves Novo Nordisk has made to make its popular diabetes and weight loss medication more widely available. Earlier this year, the company announced a direct-to-patient program called NovoCare® Pharmacy for uninsured and underinsured individuals who can pay $499 a month for Wegovy. Novo Nordisk also partnered with online telehealth companies like Ro and LifeMD to sell its pens at the same price point. The telehealth company Hims & Hers was also originally included in the partnership, but Novo Nordisk ended it after accusing the company of illegally selling compounded versions of semaglutide. Hims & Hers maintains it is providing personalized, compounded products within regulatory guidelines. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' Dave Moore, executive vice president of U.S. operations of Novo Nordisk, said in a statement. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic® self-pay offer for type 2 diabetes patients at an unprecedented price.' Sen. Bernie Sanders (I-Vt.), a prominent critic of high drug costs, called the announcement a 'modest step forward.' 'Novo Nordisk's move to cut the price of Ozempic to $499 for the uninsured is a modest step forward, but let's not forget,' Sanders said on the social media platform X. 'Ozempic costs just $59 in Germany while it costs less than $5 to make. The U.S. must no longer pay the highest prices in the world for prescription drugs.

Levi Strauss & Co. Appoints Chris Callieri as Chief Supply Chain Officer
Levi Strauss & Co. Appoints Chris Callieri as Chief Supply Chain Officer

Business Wire

time6 hours ago

  • Business Wire

Levi Strauss & Co. Appoints Chris Callieri as Chief Supply Chain Officer

SAN FRANCISCO--(BUSINESS WIRE)--Levi Strauss & Co. (LS&Co., NYSE: LEVI) today announced the appointment of Chris Callieri as senior vice president and chief supply chain officer, effective September 15. Reporting to Michelle Gass, president and chief executive officer, Callieri will join the company's executive leadership team and will be responsible for the global supply chain operations for the Levi's® brand. His responsibilities include product development, sourcing, global supply management, sustainability, and distribution and logistics. 'We're excited to welcome Chris to LS&Co. at this pivotal moment in our evolution into a DTC-first denim lifestyle company," said Gass. "With a proven track record of delivering results at scale, he's the right leader to strengthen our end-to-end supply chain agility, drive innovation, and advance our sustainability goals — all while delivering exceptional value to our fans worldwide. " Callieri brings more than 20 years of international supply chain experience in the retail and consumer goods industries. He joins LS&Co. from Victoria's Secret & Co., where he served as chief supply chain officer, leading a global team across multiple geographies and overseeing product development, sourcing, production, and distribution and logistics for various categories including intimates, apparel, accessories and beauty. Previously he was at Tory Burch, where he was pivotal in implementing systems like PLM, Merchandise Planning and SAP, and led the transformation of the supply chain. Chris has a long-standing commitment to sustainability and established Tory Burch's sustainability team and strategy. Prior to Tory Burch, Callieri held senior roles at Adidas, including senior vice president, product operations, where he was responsible for materials development, product development, sourcing and logistics for Adidas Lifestyle Brands. Callieri's extensive experience also includes leadership roles at HRC Advisory and A.T. Kearney, where he led various transformation initiatives and developed strategies to improve supply chain responsiveness and product innovation for leading retailers. 'I'm thrilled to join LS&Co. at such an exciting time for the iconic Levi's® brand, a true category leader that thrives at the center of culture," Callieri said. "I look forward to working with the talented LS&Co. team to deliver strong performance, serve our fans around the world, and strengthen Levi's® position as the world's definitive denim lifestyle brand." About Levi Strauss & Co. Levi Strauss & Co. (LS&Co.) is one of the world's largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's®, Levi Strauss Signature™ and Beyond Yoga® brands. Its products are sold in approximately 120 countries worldwide through a combination of chain retailers, department stores, online sites, and a global footprint of approximately 3,400 retail stores and shop-in-shops. Levi Strauss & Co.'s reported 2024 net revenues were $6.4 billion. For more information, go to and for financial news and announcements go to

Ligand to Participate in September Investor Conferences
Ligand to Participate in September Investor Conferences

Yahoo

time7 hours ago

  • Yahoo

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store